From: Tackling the blind spot of poor-quality medicines in Universal Health Coverage
No | Region/Country | Age-group | Disease condition | Therapeutic group of medicine | Estimated prevalence of poor-quality medicines, % | Impact | Source (Ref.) | |
---|---|---|---|---|---|---|---|---|
Estimated deaths, median | Economic costs, USD million, 2017 | Â | ||||||
1 | Sub-Saharan Africa | Under-5 | Malaria | Antimalarial | 0–40 | 122,350a | NDb | [17] |
2 | Global | Under-5 | Acute LTRIc/Pneumonia | Antimicrobials | 10 | 72,430–169,271d | NDb | [15] |
Sub-Saharan Africa | Under-5 | Malaria | Antimalarial | 7.6e | 116,000f | 38.5f | ||
3 | LMICsg | ND | ND | All | 13.6 | ND | 31250h | [18] |
4 | LMICs | All | Tuberculosis | Anti-TBi | 6.7j | 255,115 | ND | [19] |
LMICs | All | HIV/AIDS | Anti-Retroviral | 4.2j | 72,183k | ND | ||
5 | Nigeria | All | Malaria | Antimalarial | 12–50l | 12,300m | 892m | [20] |
6 | Congo (DRC)n | Under-5 | Malaria | Antimalarial | 19 | 10,370m | 151m | [21] |
7 | Uganda | Under-5 | Malaria | Antimalarial | 21–31o | 1100p | 31 | [22] |